item 1a.
risk factors.
in addition to the other information in this annual report on form 10-k, stockholders or prospective investors should carefully consider the following risk factors. if any of the events described below occurs, our business, financial condition and results of operations and future growth prospects could suffer.
risks related to baxter's business we may not achieve our long-term financial improvement goals.
we have begun implementing plans to enhance profitability and returns for our stockholders. these plans include the achievement of certain financial goals (including improved operating margin) in 2017 and beyond. while we are continuing to refine these goals, our plan contemplates significant margin expansion over our long-range plan, which runs through 2020. we have identified certain key strategies to help achieve these targets. these strategies include optimizing our core product portfolio globally, driving operational excellence through the rebasing of our cost structure and various restructuring activities and maximizing the value derived from the allocation of our capital.
as part of these strategies, we continue to evaluate the performance of all of our businesses and may sell or acquire a business or product line or exit a particular market. we are also evaluating our corporate and commercial infrastructure in the interest of streamlining costs while maintaining our commitment to quality and safety. future divestitures may result in significant write-offs, including those related to goodwill and other intangible assets. future acquisitions may fail to achieve the desired financial results (including return on investment) and synergies and may not provide the desired market access. the restructuring of our operations may not generate targeted savings or may cause unexpected disruptions to our business. as a result, we may not achieve our targeted financial results, which could have a material adverse effect on our business, financial condition or results of operations.
if we are unable to successfully introduce new products or fail to keep pace with advances in technology, our business, financial condition and results of operations could be adversely affected.
we need to successfully introduce new products to achieve our strategic business objectives. product development requires substantial investment and there is inherent risk in the research and development process. a successful product development process depends on many factors, including our ability to properly anticipate and satisfy customer needs, adapt to new technologies, obtain regulatory approvals on a timely basis, demonstrate satisfactory clinical results, manufacture products in an economical and timely manner and differentiate our products from those of our competitors. if we cannot successfully introduce new products or adapt to changing technologies, our products may become obsolete and our revenue and profitability could suffer.
issues with product supply or quality could have an adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.
our success depends upon the availability and quality of our products. the medical products industry is competitive and subject to complex market dynamics and varying demand levels. these levels vary in response to macro-economic conditions, regulatory requirements (including the availability of private or public reimbursement) and seasonality. additionally the development of new or enhanced products involves a lengthy regulatory process and is capital intensive. as a result, our ability to match our production levels and capacity to market demand is imprecise and may result in a failure to meet market demand or satisfy customer requirements for our products or, alternatively, an oversupply of inventory. failure to meet market demand may result in customers transitioning to
5
available competitive products resulting in a loss of market share or customer confidence. in the event of an oversupply, we may be forced to lower our prices or record asset impairment charges or take other action which may adversely affect our business, financial condition and results of operations.
additionally, quality management plays an essential role in determining and meeting customer requirements, preventing defects, improving the company's products and services and assuring the safety and efficacy of our products. our future success depends on our ability to maintain and continuously improve our quality management program. while we have a quality system that covers the lifecycle of our products, quality and safety issues may occur with respect to any of our products. a quality or safety issue may result in adverse inspection reports, warning letters, product recalls (either voluntary or required by the fda or similar governmental authorities in other countries) or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of a government to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses. an inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in us or our current or future products, which may result in the loss of sales and difficulty in successfully launching new products. additionally, baxter has made and continues to make significant investments in assets, including inventory and property, plant and equipment, which relate to potential new products or modifications to existing products. product quality or safety issues may restrict the company from being able to realize the expected returns from these investments, potentially resulting in asset impairments in the future.
unaffiliated third party suppliers provide a number of goods and services to our r&d, clinical and manufacturing organizations. third party suppliers are required to comply with our quality standards. failure of a third party supplier to provide compliant raw materials or supplies could result in delays, service interruptions or other quality related issues that may negatively impact our business results.
for more information on regulatory matters currently affecting us, refer to the discussion under the caption entitled "certain regulatory matters" in item 7 of this annual report on form 10-k.
we are subject to a number of existing laws and regulations, non-compliance with which could adversely affect our business, financial condition and results of operations, and we are susceptible to a changing regulatory environment.
as a participant in the healthcare industry, our operations and products, and those of our customers, are regulated by numerous government agencies, both inside and outside the united states. the impact of this on us is direct to the extent we are subject to these laws and regulations, and indirect in that in a number of situations, even though we may not be directly regulated by specific healthcare laws and regulations, our products must be capable of being used by our customers in a manner that complies with those laws and regulations.
the manufacture, distribution, marketing and use of our products are subject to extensive regulation and scrutiny by fda and other regulatory authorities globally. any new product must undergo lengthy and rigorous testing and other extensive, costly and time-consuming procedures mandated by fda and foreign regulatory authorities. changes to current products may be subject to vigorous review, including additional 510(k) and other regulatory submissions, and approvals are not certain. our facilities must be approved and licensed prior to production and remain subject to inspection from time to time thereafter. failure to comply with the requirements of fda or other regulatory authorities, including a failed inspection or a failure in our adverse event reporting system, could result in adverse inspection reports, warning letters, product recalls or seizures, monetary sanctions, injunctions to halt the manufacture and distribution of products, civil or criminal sanctions, refusal of a government to grant approvals or licenses, restrictions on operations or withdrawal of existing approvals and licenses. any of these actions could cause a loss of customer confidence in us and our products, which could adversely affect our sales. the requirements of regulatory authorities, including interpretative guidance, are subject to change and compliance with additional or changing requirements or interpretative guidance may subject the company to further review, result in product launch delays or otherwise increase our costs. for information on current regulatory issues affecting us, please refer to the caption entitled "certain regulatory matters" in item 7 of this annual report on form 10-k. in connection with these issues, there can be no assurance that additional costs or civil and criminal penalties will not be incurred, that additional regulatory actions with respect to the company will not occur, that the company will not face civil claims for damages from purchasers or users, that substantial additional charges or significant asset impairments may not be required, that sales of other products may not be adversely affected, or that additional regulation will not be introduced that may adversely affect the company's operations and consolidated financial statements.
the sales, marketing and pricing of products and relationships that pharmaceutical and medical device companies have with healthcare providers are under increased scrutiny by federal, state and foreign government agencies. compliance with the anti-kickback statute, false claims act, food, drug and cosmetic act (including as these laws relate to off-label promotion of products) and other healthcare related laws, as well as competition, data and patient privacy and export and import laws, is under increased focus by the agencies charged with overseeing such activities, including fda, oig, doj and the federal trade commission. the doj and the securities and exchange commission have also increased their focus on the enforcement of the u.s. foreign corrupt practices act
6
(fcpa), particularly as it relates to the conduct of pharmaceutical and medical product companies. the fcpa and similar anti-bribery laws generally prohibit companies and their employees, contractors or agents from making improper payments to government officials for the purpose of obtaining or retaining business. healthcare professionals in many countries are employed by the government and consequently may be considered government officials. foreign governments have also increased their scrutiny of pharmaceutical and medical product companies' sales and marketing activities and relationships with healthcare providers and competitive practices generally. the laws and standards governing the promotion, sale and reimbursement of our products and those governing our relationships with healthcare providers and governments, including the sunshine act enacted under the patient protection and affordable care act, can be complicated, are subject to frequent change and may be violated unknowingly.
additionally, the u.s. department of the treasury's office of foreign control and the bureau of industry and security at the u.s. department of commerce administer laws and regulations that restrict u.s. persons and, in some instances, non-u.s. persons, in conducting activities, transacting business or making investments in certain countries, governments, entities and individuals subject to u.s. economic sanctions. from time to time, certain of our subsidiaries have limited business dealings in countries subject to these sanctions, including iran, sudan, syria, cuba, and russia. these dealings represent an insignificant amount of our consolidated revenues and income but expose us to an increased risk of violating applicable sanctions regulations, which are complex and subject to frequent change. additional restrictions may be enacted, enforced or interpreted in a way that may adversely affect our operations.
we have compliance programs in place, including policies, training and various forms of monitoring, designed to address the risks discussed above. nonetheless, these programs and policies may not always protect us from conduct by individual employees that violate these laws. violations or allegations of violations of these laws may result in large civil and criminal penalties, debarment from participating in government programs, diversion of management time, attention and resources and may otherwise have an adverse effect on our business, financial condition and results of operations. for more information related to the company's ongoing government investigations, please refer to note 16 in item 8 of this annual report on form 10-k.
the laws and regulations discussed above are broad in scope and subject to evolving interpretations, which could require us to incur substantial cost associated with compliance or to alter one or more of our sales and marketing practices and may subject us to enforcement actions which could adversely affect our business, financial condition and results of operations.
if reimbursement or other payment for our current or future products is reduced or modified in the united states or abroad, including through the implementation of government-sponsored healthcare reform or other similar actions, cost containment measures, or changes to policies with respect to pricing, taxation or rebates, then our business could suffer.
sales of our products depend, in part, on the extent to which the costs of our products are paid by both public and private payers. these payers include medicare, medicaid, and private health care insurers in the united states and foreign governments and third-party payers outside the united states. public and private payers are increasingly challenging the prices charged for medical products and services. we may continue to experience continued downward pricing pressures from any or all of these payers which could result in an adverse effect on our business, financial condition and operational results.
global efforts toward healthcare cost containment continue to exert pressure on product pricing. governments around the world use various mechanisms to control healthcare expenditures such as price controls, the formation of public contracting authorities, product formularies (lists of recommended or approved products), and competitive tenders which require the submission of a bid to sell products. sales of our products are dependent, in part, on the availability of reimbursement by government agencies and healthcare programs, as well as insurance companies and other private payers. in much of europe, latin america, asia and australia, for example, the government provides healthcare at low cost to patients, and controls its expenditures by purchasing products through public tenders, collective purchasing, regulating prices, setting reference prices in public tenders or limiting reimbursement or patient access to certain products. additionally, austerity measures or other reforms by foreign governments may limit, reduce or eliminate payments for our products and adversely affect both pricing flexibility and demand for our products.
for example, in the united states the patient protection and affordable care act (ppaca), which was signed into law in march 2010, includes several provisions which impact our businesses in the united states, including increased medicaid rebates and an expansion of the 340b drug pricing program which provides certain qualified entities, such as hospitals serving disadvantaged populations, with discounts on the purchase of drugs for outpatient use and an excise tax on the sale of certain drugs. the ppaca reduces medicare and medicaid payments to hospitals and other providers, which may cause us to experience downward pricing pressure. members of congress and the executive branch have made statements suggesting plans to seek repeal of all or portions of the ppaca. because of the continued uncertainty about the implementation of the ppaca, including the potential for legal challenges or repeal of that legislation, we cannot quantify or predict the likely impact of any change in or replacement of the ppaca on our business and the demand for our products.
7
as a result of these and other measures, including future measures or reforms that cannot be predicted, reimbursement may not be available or sufficient to allow us to sell our products on a competitive basis. legislation and regulations affecting reimbursement for our products may change at any time and in ways that may be adverse to us. we cannot predict the impact of these pressures and initiatives, or any negative effects of any additional regulations that may affect our business.
there is substantial competition in the product markets in which we operate.
although no single company competes with us in all of our businesses, we face substantial competition in both of our segments from international and domestic healthcare and pharmaceutical companies and providers of all sizes, and these competitors often differ across our businesses. competition is primarily focused on cost-effectiveness, price, service, product performance, and technological innovation.
competition may increase further as additional companies begin to enter our markets or modify their existing products to compete directly with ours. if our competitors respond more quickly to new or emerging technologies and changes in customer requirements or we do not introduce new versions or upgrades to our product portfolio in response to those requirements, our products may be rendered obsolete or non-competitive. if our competitors develop more effective or affordable products, or achieve earlier patent protection or product commercialization than we do, our operations will likely be negatively affected. if we are forced to reduce our prices due to increased competition, our business could become less profitable. the company's sales could be adversely affected if any of its contracts with gpos, idns or other customers are terminated due to increased competition or otherwise.
if our business development activities are unsuccessful, our business could suffer and our financial performance could be adversely affected.
as part of our long-term strategy, we are engaged in business development activities including evaluating acquisitions, joint development opportunities, technology licensing arrangements and other opportunities. these activities may result in substantial investment of the company's resources. our success developing products or expanding into new markets from such activities will depend on a number of factors, including our ability to find suitable opportunities for acquisition, investment or alliance; whether we are able to complete an acquisition, investment or alliance on terms that are satisfactory to us; the strength of the other company's underlying technology, products and ability to execute its business strategies; any intellectual property and litigation related to these products or technology; and our ability to successfully integrate the acquired company, business, product, technology or research into our existing operations, including the ability to adequately fund acquired in-process research and development projects and to maintain adequate controls over the combined operations. certain of these activities are subject to antitrust and competition laws, which laws could impact our ability to pursue strategic transactions and could result in mandated divestitures in the context of proposed acquisitions. if we are unsuccessful in our business development activities, we may be unable to meet our financial targets and our financial performance could be adversely affected.
for more information on recent business development activities, see note 5 in item 8 of this annual report on form 10-k.
if we are unable to obtain sufficient components or raw materials on a timely basis or if we experience other manufacturing or supply difficulties, our business may be adversely affected.
the manufacture of our products requires the timely delivery of sufficient amounts of quality components and materials. we manufacture our products in approximately 50 manufacturing facilities around the world. we acquire our components and materials from many suppliers in various countries. we work closely with our suppliers to ensure the continuity of supply but we cannot guarantee these efforts will always be successful. further, while efforts are made to diversify our sources of components and materials, in certain instances we acquire components and materials from a sole supplier. for most of our components and materials for which a sole supplier is used, we believe that alternative sources of supply exist and have made a strategic determination to use a sole supplier. in very limited instances, however, we do rely upon sole supplier relationships for which no alternatives have currently been identified. although we do carry strategic inventory and maintain insurance to mitigate the potential risk related to any related supply disruption, there can be no assurance that such measures will be effective. due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials. a reduction or interruption in supply, and an inability to develop alternative sources for such supply, could adversely affect our ability to manufacture our products in a timely or cost-effective manner, and our ability to make product sales.
many of our products are difficult to manufacture. this is due to the complex nature of manufacturing pharmaceuticals, including biologics, and devices, as well as the strict regulatory regime governing our manufacturing operations. variations in the manufacturing process may result in production failures which could lead to launch delays, product shortage, unanticipated costs, lost revenues and damage to our reputation. a failure to identify and address manufacturing problems prior to the release of products to our customers may also result in a quality or safety issue of the type discussed above.
8
some of our products are manufactured at a single manufacturing facility or stored at a single storage site. loss or damage to a manufacturing facility or storage site due to a natural disaster or otherwise could adversely affect our ability to manufacture sufficient quantities of key products or otherwise deliver products to meet customer demand or contractual requirements which may result in a loss of revenue and other adverse business consequences. because of the time required to approve and license a manufacturing facility a third party manufacturer may not be available on a timely basis to replace production capacity in the event we lose manufacturing capacity or products are otherwise unavailable due to natural disaster, regulatory action or otherwise.
if we are unable to protect our patents or other proprietary rights, or if we infringe the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.
patent and other proprietary rights are essential to our business. our success depends to a significant degree on our ability to obtain and enforce patents and licenses to patent rights, both in the united states and in other countries. we cannot guarantee that pending patent applications will result in issued patents, that patents issued or licensed will not be challenged or circumvented by competitors, that our patents will not be found to be invalid or that the intellectual property rights of others will not prevent the company from selling certain products or including key features in the company's products.
the patent position of a healthcare company is often uncertain and involves complex legal and factual questions. significant litigation concerning patents and products is pervasive in our industry. patent claims include challenges to the coverage and validity of our patents on products or processes as well as allegations that our products infringe patents held by competitors or other third parties. a loss in any of these types of cases could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations. we also rely on trademarks, copyrights, trade secrets and know-how to develop, maintain and strengthen our competitive positions. third parties may know, discover or independently develop equivalent proprietary information or techniques, or they may gain access to our trade secrets or disclose our trade secrets to the public.
although our employees, consultants, parties to collaboration agreements and other business partners are generally subject to confidentiality or similar agreements to protect our confidential and proprietary information, these agreements may be breached, and we may not have adequate remedies for any breach. to the extent that our employees, consultants, parties to collaboration agreements and other business partners use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.
furthermore, our intellectual property, other proprietary technology and other sensitive company data is potentially vulnerable to loss, damage or misappropriation from system malfunction, computer viruses, unauthorized access to our data or misappropriation or misuse thereof by those with permitted access and other events. while we have invested to protect our intellectual property and other data, and continue to work diligently in this area, there can be no assurance that our precautionary measures will prevent breakdowns, breaches, cyber incidents or other events. such events could have a material adverse effect on our reputation, business, financial condition or results of operations.
misappropriation or other loss of our intellectual property from any of the foregoing would have an adverse effect on our competitive position and may cause us to incur substantial litigation costs.
we are subject to risks associated with doing business globally.
our operations are subject to risks inherent in conducting business globally and under the laws, regulations and customs of various jurisdictions and geographies. these risks include changes in exchange controls and other governmental actions, loss of business in government and public tenders that are held annually in many cases, increasingly complex labor environments, availability of raw materials, changes in taxation, export control restrictions, changes in or violations of u.s. or local laws, including the fcpa and the united kingdom bribery act, dependence on a few government entities as customers, pricing restrictions, economic and political instability (including instability as it relates to the euro and currencies in certain emerging market countries), disputes between countries, diminished or insufficient protection of intellectual property, and disruption or destruction of operations in a significant geographic region regardless of cause, including war, terrorism, riot, civil insurrection or social unrest. failure to comply with, or material changes to, the laws and regulations that affect our global operations could have an adverse effect on our business, financial condition or results of operations.
the 2016 referendum by british voters to exit the european union (eu) (commonly known as brexit) has created uncertainties affecting business operations in the eu. the uk government is expected to initiate a process to withdraw from the eu in the coming months. a withdrawal could result in the deterioration of economic conditions, volatility in currency exchange rates (as evidenced by the deterioration in the value of the british pound as compared to the u.s. dollar following the brexit vote), and increased regulatory complexities.  these outcomes could have an adverse effect on our business, financial condition or results of operations.
9
changes in foreign currency exchange rates and interest rates could have a material adverse effect on our operating results and liquidity.
we generate the majority of our revenue and profit outside the united states. as a result, our financial results may be adversely affected by fluctuations in foreign currency exchange rates. we cannot predict with any certainty changes in foreign currency exchange rates or our ability to mitigate these risks. we may experience additional volatility as a result of inflationary pressures and other macroeconomic factors in certain emerging market countries. we are also exposed to changes in interest rates, and our ability to access the money markets and capital markets could be impeded if adverse liquidity market conditions occur. a discussion of the financial impact of foreign exchange rate and interest rate fluctuations, and the ways and extent to which we attempt to mitigate such impact is contained under the caption "financial instrument market risk" in item 7 of this annual report on form 10-k.
changes in tax laws or exposure to additional income tax liabilities may have a negative impact on our operating results.
tax policy reform continues to be a topic of discussion in the united states. members of the newly installed u.s. congress, including the speaker of the house paul ryan, have identified comprehensive tax reform as a priority for 2017. a significant change to the tax system in the united states, including changes to the taxation of international income or imported product, could have an adverse effect upon our results of operations. because we operate in multiple income tax jurisdictions both inside and outside the united states, cross border transactions among our affiliates are a significant part of the manner in which we operate. although we believe that we transact intercompany business in accordance with arms-length principles, taxing authorities may audit us from time to time, disagree with certain positions we have taken and assess additional taxes. we regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax provision. however, we may not accurately predict the outcome of these audits, and as a result the actual outcome of these audits may have an adverse impact on our financial results. for more information on ongoing audits, see note 15 in item 8 of this annual report on form 10-k.
we are increasingly dependent on information technology systems and subject to privacy and security laws, and our systems and infrastructure face certain risks, including from cyber security breaches and data leakage.
we increasingly rely upon technology systems and infrastructure. our technology systems are potentially vulnerable to breakdown or other interruption by fire, power loss, system malfunction, unauthorized access and other events. likewise, data privacy breaches by employees and others with both permitted and unauthorized access to our systems and products may pose a risk that sensitive data (including protected health information (phi)) may be exposed to unauthorized persons or to the public, or may be permanently lost. the increasing use and evolution of technology, including cloud-based computing, creates additional opportunities for the unintentional dissemination of information, intentional destruction of confidential information stored in our systems, products or in non-encrypted portable media or storage devices. we could also experience a business interruption, information theft of confidential information, or reputational damage from industrial espionage attacks, malware or other cyber incidents, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers or other business partners. as our products continue to evolve, third-parties may attempt to access or obtain proprietary information from our products or systems. additionally, we must comply with numerous federal and state laws and regulations governing the collection, dissemination, access, use, security and phi, including the health insurance portability and accountability act of 1996 and its implementing privacy and security regulations. while we have invested heavily in the protection of data and information technology and in related training, there can be no assurance that our efforts will prevent significant breakdowns, breaches in our systems or other cyber incidents or ensure compliance with all applicable security and privacy laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information, including phi, on our behalf. any such breakdown, breach, incident or failure to comply could have a material adverse effect upon our reputation, business, operations or financial condition. in addition, significant implementation issues may arise as we continue to consolidate and outsource certain computer operations and application support activities.
if we fail to attract and retain key employees our business may suffer.
our ability to compete effectively depends on our ability to attract and retain key employees, including people in senior management, sales, marketing and research positions. competition for top talent in healthcare can be intense. our ability to recruit and retain such talent will depend on a number of factors, including hiring practices of our competitors, compensation and benefits, work location, work environment and industry economic conditions. if we cannot effectively recruit and retain qualified employees, our business could suffer.
we are subject to a number of pending lawsuits.
we are a defendant in a number of pending lawsuits. in addition, we may be named as a defendant in future patent, product liability or other lawsuits. these current and future matters may result in a loss of patent protection, reduced revenue, significant liabilities and
10
diversion of our management's time, attention and resources. given the uncertain nature of litigation generally, we are not able in all cases to estimate the amount or range of loss that could result from an unfavorable outcome in these current matters. in view of these uncertainties, the outcome of these matters may result in charges in excess of any established reserves, and, to the extent available, liability insurance. we also continue to be self-insured with respect to product liability claims. the absence of third-party insurance coverage for current or future claims increases our potential exposure to unanticipated claims and adverse decisions. protracted litigation, including any adverse outcomes, may have an adverse impact on the business, operations or financial condition of the company. even claims without merit could subject us to adverse publicity and require us to incur significant legal fees. see note 16 in item 8 of this annual report on form 10-k for more information regarding current lawsuits.
current or worsening economic conditions may adversely affect our business and financial condition.
the company's ability to generate cash flows from operations could be affected if there is a material decline in the demand for the company's products, in the solvency of its customers or suppliers, or deterioration in the company's key financial ratios or credit ratings. current or worsening economic conditions may adversely affect the ability of our customers (including governments) to pay for our products and services, and the amount spent on healthcare generally. this could result in a decrease in the demand for our products and services, declining cash flows, longer sales cycles, slower adoption of new technologies and increased price competition. these conditions may also adversely affect certain of our suppliers, which could cause a disruption in our ability to produce our products. we continue to do business with foreign governments in certain countries, including greece, spain, portugal, and italy, which have experienced deterioration in credit and economic conditions. as of december 31, 2016, the company's net accounts receivable from the public sector in greece, spain, portugal and italy totaled $137 million. while global economic conditions have not significantly impacted the company's ability to collect receivables, liquidity issues in certain countries have resulted, and may continue to result, in delays in the collection of receivables and credit losses. these conditions may also impact the stability of the euro or yuan. for more information on accounts receivable and credit matters with respect to certain of these countries, refer to the discussion under the caption entitled "credit facilities, access to capital and credit ratings" in item 7 of this annual report on form 10-k.
we may incur operational difficulties or be exposed to claims and liabilities as a result of the separation and distribution.
on july 1, 2015, we distributed approximately 80.5% of the outstanding shares of baxalta common stock to baxter stockholders in connection with the separation of our biopharmaceuticals business. we disposed of our remaining 19.5% stake in baxalta (retained shares) in 2016, in connection with a series of transactions including debt-for-equity exchanges, an equity-for-equity exchange and a contribution to our u.s. pension plan (retained shares transactions). shire plc (shire) acquired baxalta in june 2016, after completion of the last retained shares transaction. in connection with the july 2015 distribution, we entered into a separation and distribution agreement and various other agreements (including a transition services agreement, a tax matters agreement, a long term services agreement, a manufacturing and supply agreement, an employee matters agreement, a trademark license agreement, a galaxy license agreement, an international commercial operations agreement, a shareholders' and registration rights agreement and certain other commercial agreements) with baxalta. these agreements govern the separation and distribution and the relationship between the companies going forward, including with respect to potential tax-related losses associated with the separation and distribution and the retained shares transactions. they also provide for the performance of services by each company for the benefit of the other for a period of time (including under the manufacturing and supply agreement pursuant to which shire now manufactures and sells certain products and materials to us).
the separation and distribution agreement provides for indemnification obligations designed to make baxalta financially responsible for many liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation. it is possible that a court would disregard the allocation agreed to between us and baxalta and require us to assume responsibility for obligations allocated to baxalta. third parties could also seek to hold us responsible for any of these liabilities or obligations, and the indemnity rights we have under the separation and distribution agreement may not be sufficient to fully cover all of these liabilities and obligations. even if we are successful in obtaining indemnification, we may have to bear costs temporarily. in addition, our indemnity obligations to baxalta may be significant. these risks could negatively affect our business, financial condition or results of operations.
the separation of baxalta continues to involve a number of risks, including, among other things, the indemnification risks described above and the potential that management's and our employees' attention will be significantly diverted by the provision of transitional services. certain of the agreements described above provide for the performance of services by each company for the benefit of the other for a period of time. shire may elect to extend the term for which we provide services to baxalta under these agreements. if baxalta is unable to satisfy its obligations under these agreements, including its indemnification obligations, we could incur losses. these arrangements could also lead to disputes over rights to certain shared property and rights and over the allocation of costs and revenues for products and operations. our inability to effectively manage the separation activities and related events could adversely affect our business, financial condition or results of operations.
11
there could be significant liability if the separation and distribution or any retained shares transaction is determined to be a taxable transaction. baxalta has indemnified us for certain potential liabilities that may arise, and such indemnification obligation is guaranteed by shire, but baxalta and shire may be unable to satisfy their indemnification obligations to us in the future.
the separation and distribution and the retained shares transactions (collectively, the baxter transactions) qualify for tax-free treatment to baxter and its stockholders under the internal revenue code of 1986, as amended (the code). completion of the separation and distribution was conditioned upon, among other things, the receipt of a private letter ruling from the irs regarding certain issues relating to the tax-free treatment of the baxter transactions. although the irs private letter ruling is generally binding on the irs, the continuing validity of such ruling is subject to the accuracy of factual representations and assumptions made in the ruling. completion of the distribution was also conditioned upon baxter's receipt of a tax opinion from kpmg llp regarding certain aspects of the baxalta spin-off not covered by the irs private letter ruling. the opinion was based upon various factual representations and assumptions, as well as certain undertakings made by baxter and baxalta. if any of the factual representations or assumptions in the irs private letter ruling or tax opinion is untrue or incomplete in any material respect, if any undertaking is not complied with, or if the facts upon which the irs private letter ruling or tax opinion are based are materially different from the actual facts relating to the baxter transactions, the opinion or irs private letter ruling may not be valid. moreover, opinions of a tax advisor are not binding on the irs. as a result, the conclusions expressed in the opinion of a tax advisor could be successfully challenged by the irs.
if the baxter transactions are determined to be taxable, baxter and its stockholders could incur significant tax liabilities. pursuant to the tax matters agreement, baxalta agreed to indemnify us for certain tax-related losses incurred if baxalta's actions cause the separation and distribution and certain related transactions to fail to qualify for tax-free status under the applicable provisions of the code.
in anticipation of the proposed baxalta - shire merger (the merger), we entered into a letter agreement with shire and baxalta (the letter agreement). under the letter agreement, baxalta agreed to indemnify, and shire agreed to guarantee such indemnity to, baxter and each of its affiliates and each of their respective officers, directors and employees against certain tax-related losses attributable to or resulting from (in whole or in part) the merger as further described in the letter agreement. if the baxter transactions are determined to be taxable as a result (in whole or in part) of the merger (for example, if the merger is deemed to be part of a plan (or series of related transactions) that includes the baxter transactions), baxter and its stockholders could incur significant tax liabilities. although baxalta and shire may be required to indemnify baxter under the tax matters agreement and the letter agreement for any such tax liabilities incurred by baxter, there can be no assurance that the indemnity from baxalta or the guarantee thereof by shire will be sufficient to protect us against all or a part of the amount of such liabilities, or that either baxalta or shire will be able to fully satisfy their respective obligations.
even if we ultimately succeed in recovering from baxalta or shire any amounts for which we are held liable, we may be temporarily required to bear these costs ourselves, which could negatively affect our business, results of operations and financial condition.
item 7.   management's discussion and analysis of financial condition and results of operations.

the following commentary should be read in conjunction with the consolidated financial statements and accompanying notes.
executive overview description of the company and business segments baxter international inc., through its subsidiaries, provides a broad portfolio of essential renal and hospital products, including acute and chronic dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition therapies; premixed and oncolytic injectables; biosurgery products and anesthetics; drug reconstitution systems; and pharmacy automation, software and services. the company's global footprint and critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. these products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.
separation of baxalta incorporated on july 1, 2015, baxter completed the distribution of approximately 80.5% of the outstanding common stock of its biopharmaceuticals business, baxalta incorporated (baxalta), to baxter stockholders (the distribution). as a result of the separation, the operating results of baxalta have been reflected as discontinued operations for the years ended december 31, 2016, 2015, and 2014. refer to note 2 in item 8 for additional information regarding the separation of baxalta. unless otherwise stated, financial results herein reflect continuing operations.
segments baxter operates under two reportable segments, hospital products and renal. refer to note 14 in item 8 for additional information regarding the company's segments.
the segments and a description of their products and services are as follows:
the hospital products business manufactures sterile intravenous (iv) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, parenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products. the business also provides products and services related to pharmacy compounding, and drug formulation; sterile iv solutions; infusion systems and devices; parenteral nutrition therapies; premixed and oncolytic injectables; biosurgery products and anesthetics; drug reconstitution systems; and pharmacy automation, software and services.
the renal business offers a comprehensive portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (pd), hemodialysis (hd), continuous renal replacement therapy (crrt) and additional dialysis services.
baxter has approximately 48,000 employees and conducts business in over 100 countries. the company generates approximately 60% of its revenues outside the united states, and maintains approximately 50 manufacturing facilities and over 100 distribution facilities in the united states, europe, asia-pacific, latin america and canada.
financial results baxter's global net sales totaled $10.2 billion in 2016, an increase of 2% over 2015, including an unfavorable foreign currency impact of two percentage points. international sales totaled $5.9 billion in 2016, a decrease of 1% compared to 2015, including an unfavorable foreign currency impact of four percentage points. sales in the united states totaled $4.3 billion in 2016, an increase of 6% compared to 2015.
baxter's income from continuing operations for 2016 totaled $5.0 billion or $9.01 per diluted share, compared to $393 million, or $0.72 per diluted share, in the prior year. income from continuing operations in 2016 included special items which resulted in a net increase to income from continuing operations of $3.9 billion, or $7.05 per diluted share. income from continuing operations in 2015 included special items which resulted in a net reduction to income from continuing operations of $362 million, or $0.66 per diluted share. the company's special items are discussed further in the results of operations section below.
18
baxter's financial results included r&d expenses totaling $647 million in 2016, which reflects the company's focus on balancing increased investments to support the company's new product pipeline with efforts to optimize overall r&d spending through continuous evaluation of the portfolio.
the company's financial position remains strong, with operating cash flows from continuing operations totaling $1.6 billion in 2016. the company has continued to execute on its disciplined capital allocation framework, which is designed to optimize stockholder value creation through reinvestment in the businesses, dividends and targeted share repurchases, as well as acquisitions and other business development initiatives as discussed in the strategic objectives section below.
capital investments totaled $719 million in 2016 as the company continues to invest across its businesses to support future growth, including additional investments in support of new and existing product capacity expansions. the company's investments in capital expenditures in 2016 were focused on projects that improve production efficiency and enhance manufacturing capabilities to support its strategy of geographic expansion with select investments in growing markets.
the company also continued to return value to its stockholders in the form of dividends. during 2016, the company paid cash dividends to its shareholders totaling $268 million. additionally, in 2016 the company repurchased 17.8 million shares through cash repurchases and an equity-for-equity exchange of retained shares for outstanding baxter shares.
strategic objectives baxter continues to focus on several key objectives to successfully execute its long-term strategy to achieve sustainable growth and deliver enhanced stockholder value. baxter's diversified and broad portfolio of medical products that treat life-threatening acute or chronic conditions and its global presence are core components of the company's strategy to achieve these objectives. the company is focused on three strategic factors as part of its pursuit of industry leading performance: optimizing its core portfolio globally; operational excellence focused on streamlining the cost structure and enhancing operational efficiency; and following a disciplined and balanced approach to capital allocation.
optimizing the core portfolio globally baxter has categorized its product portfolio into four strategic business groupings.  those groupings include core growth, core return on capital, maintain or manage differently and strategic bets.  within the core growth grouping, baxter looks to invest for long-term, higher margin growth.  baxter looks to optimize its return on investment and to maintain or enhance its market position with its core return on capital products.  maintain or manage differently products are those for which baxter looks to sustain or reposition its underlying investment.  finally, the strategic bet grouping includes products for which baxter is evaluating its market position and investment strategy.  these products cover mature and emerging markets.  while baxter has made an initial assignment of each of its product categories to one of the business groupings described above, baxter continues to evaluate each product category's placement in light of shifting market dynamics and company priorities and may reassign a product category into a different business grouping from time to time.
as part of this portfolio review, baxter seeks to optimize its position in product areas where the company has a stable, profitable business model, identify and alter investments in products that have reached the end of their life cycles or with respect to which market positions have evolved unfavorably. in the course of doing so, baxter expects to continue to reallocate capital to more promising opportunities or business groupings, as described above.
as part of this strategy, baxter is shifting its investments to drive innovation where it has compelling opportunities to serve patients and healthcare professionals while advancing the business and will accelerate the pace in bringing these advances to market. baxter is in the midst of launching more than 100 products by 2020 in such areas as chronic and acute renal care; smart pump technology; hospital pharmaceuticals and nutritionals; surgical sealants, and more. these comprise a mix of entirely new offerings, marked improvements on existing technologies, and the expansion of current products into new geographies.
operational excellence as part of its pursuit of improved margin performance, baxter is working to optimize its cost structure, consistent with its emergence as a stand-alone medical products company and as such is critically assessing optimal support levels in light of the company's ongoing portfolio optimization efforts.
the company intends to continue to actively manage its cost structure to help ensure it is committing resources to the highest value uses. such high value activities include supporting innovation, building out the portfolio, expanding patient access and accelerating growth for the company's stockholders.
19
baxter has undertaken a comprehensive review of all aspects of its operations and has already begun to implement changes in line with its business goals.
maintaining disciplined and balanced capital allocation baxter's capital allocation strategies include the following:
   reinvest in the business, by funding opportunities that are positioned to deliver sustainable growth, support the company's innovation efforts and improve margin performance;

   return capital to stockholders through stock dividends, to meaningfully increase with earnings growth;

   targeted share repurchases; and

   identify and pursue accretive m&amp;a opportunities that generate returns above targeted thresholds.

responsible corporate citizen the company strives for continued growth and profitability, while furthering its focus on acting as a responsible corporate citizen. at baxter, sustainability means creating lasting social, environmental and economic value by addressing the needs of the company's wide-ranging stakeholder base. baxter's comprehensive sustainability program is focused on areas where the company is uniquely positioned to make a positive impact. priorities include providing employees a safe, healthy and inclusive workplace, fostering a culture that drives integrity, strengthening access to healthcare, enhancing math and science education, and driving environmental performance across the product life cycle including development, manufacturing and transport. baxter and the baxter international foundation provide financial support and product donations in support of critical needs, from assisting underserved communities to providing emergency relief for countries experiencing natural disasters.
throughout 2016 the company continued to implement a range of water conservation strategies and facility-based energy saving initiatives. in the area of product stewardship and life cycle management, baxter is pursuing efforts such as sustainable design and reduced packaging. baxter is also responding to the challenges of climate change through innovative greenhouse gas emissions-reduction programs, such as shifting to less carbon-intensive energy sources in manufacturing and transport. additionally, the company developed new long-term goals to drive continued environmental stewardship while creating healthier, more sustainable communities where baxter employees work and live.
risk factors the company's ability to sustain long-term growth and successfully execute the strategies discussed above depends in part on the company's ability to manage within an increasingly competitive and regulated environment and to address the other risk factors described in item 1a of this annual report on form 10-k.
20
results of operations special items the following table provides a summary of the company's special items and the related impact by line item on the company's results of continuing operations for 2016, 2015 and 2014.
years ended december 31 (in millions)                  2016                     2015                    2014

gross margin intangible asset amortization expense                               $(163   )               $(158   )               $(168   )
business optimization items1                                         (156   )                 (38   )                  11
intangible asset impairment2                                          (51   )                   -                       -
separation-related costs3                                              (1   )                   -                       -
product-related items4                                                 18                      28                     (64   )
total special items                                                 $(353   )               $(168   )               $(221   )
impact on gross margin ratio                                    (3.5 pts)               (1.7 pts)               (2.1 pts)
marketing and administrative expenses business optimization items1                                         $173                    $152                    $115
separation-related costs3                                              53                     110                      11
product-related items4                                                  -                       -                       4
branded prescription drug fee5                                          -                       -                       3
total special items                                                  $226                    $262                    $133
impact on marketing and administrative expense ratio              2.3 pts                 2.6 pts                 1.2 pts research and development expenses business optimization items1                                          $80                     $13                      $2
separation-related costs3                                               -                       1                       -
total special items                                                   $80                     $14                      $2
other (income) expense, net business optimization items1                                           $-                     $(3   )                 $25
net realized gains on retained shares transactions6                (4,391   )                   -                       -
loss on debt extinguishment7                                          149                     130                       -
reserve items and adjustments8                                          -                     (52   )                   1
business development items9                                             -                     (20   )                   -
tax matter10                                                            9                       -                       -
total special items                                               $(4,233   )                 $55                     $26
income tax expense impact of special items10                                           $(314   )               $(137   )               $(137   )
total special items                                                 $(314   )               $(137   )               $(137   )
impact on effective tax rate                                   (22.1 pts)              (10.4 pts)              (12.8 pts)
intangible asset amortization expense is identified as a special item to facilitate an evaluation of current and past operating performance and is similar to how management internally assesses performance. additional special items are identified above because they are highly variable, difficult to predict and of a size that may substantially impact the company's reported operations for a period. management believes that providing the separate impact of the above items on the company's results in accordance with generally accepted accounting principles (gaap) in the united states may provide a more complete understanding of the company's operations and can facilitate a fuller analysis of the company's results of operations, particularly in evaluating performance from one period to another. this information should be considered in addition to, and not as a substitute for, information prepared in accordance with gaap.
1   in 2016, 2015 and 2014, the company's results were impacted by costs associated with the company's execution of certain strategies to optimize its organization and global cost structure on a global basis. these actions included streamlining the company's international operations, rationalizing its manufacturing facilities, reducing its general and administrative infrastructure, re-aligning certain r&amp;d activities and cancelling certain r&amp;d programs. the company recorded net business optimization charges of $409 million, $200 million and $131 million in 2016, 2015 and 2014, respectively. the company's results in 2016 included a net charge of $285 million related to restructuring activities, $65 million of costs to implement business optimization programs which primarily included external consulting and project employee costs, $33 million of accelerated depreciation associated with facilities to be closed, and $26 million of gambro integration costs. the $285 million of

21
restructuring charges included net $180 million of employee termination costs, $54 million of costs related to the discontinuance of the vivia home hemodialysis development program, $47 million of asset impairment charges related to acquired in-process r&amp;d and facility closure costs and $4 million of other exit costs. the company's results in 2015 included a net charge of $127 million related to restructuring activities and $73 million of gambro integration costs. the $127 million of net restructuring charges included net $91 million of employee termination costs, a $20 million intangible asset impairment and $16 million of other asset impairments and other exit costs. the company's results in 2014 included $144 million of gambro integration costs and a net benefit of $13 million from adjustments for reserves that are no longer probable of being utilized. refer to note 7 in item 8 for further information regarding these charges and related reserves.

2   the company's results in 2016 included a $51 million asset impairment primarily related to developed technology.

3   the company's results in 2016, 2015 and 2014 included costs related to the baxalta separation of $54 million, $111 million and $11 million, respectively.

4   the company's results in 2016 and 2015 included a net benefit of $18 million and $28 million, respectively, primarily related to adjustments to the colleague and sigma spectrum infusion pump reserves. the company's results in 2014 included charges, net of reversals, of $68 million primarily related to product remediation efforts for the sigma spectrum infusion pump. refer to note 7 in item 8 for further information regarding these charges and related reserves.

5   the company's results in 2014 included a charge of $3 million to account for an additional year of the branded prescription drug fee in accordance with final regulations issued in the third quarter of 2014 by the internal revenue service.

6   the company's results in 2016 included net realized gains of $4.4 billion related to the debt-for-equity exchanges of the company's retained shares in baxalta for certain indebtedness, the exchange of retained shares in baxalta for baxter shares and the contribution of retained shares in baxalta to baxter's u.s. pension fund.

7   the company's results in 2016 included a net debt extinguishment loss totaling $149 million related to the march 2016 debt-for-equity exchange for certain company indebtedness and certain debt redemptions. the company's results in 2015 included a loss of $130 million related to its july 2015 tender offer, for certain of its outstanding indebtedness. refer to note 8 in item 8 for additional information.

8   the company's results in 2015 included income of $52 million related to a litigation settlement in which baxter was the beneficiary. the company's results in 2014 included income of $1 million related to third-party recoveries and reversals of prior litigation reserves.

9   the company's results in 2015 included a benefit of $20 million relating to the reversal of contingent consideration milestone liabilities. refer to note 5 in item 8 for further information regarding the company's acquisitions and other arrangements.

10   the company's results in 2016 included a net after-tax benefit of $10 million, related to the settlement of an income tax matter in the company's non-wholly owned joint venture in turkey. this amount was comprised of $19 million included in income tax expense offset by $9 million in non-controlling interest recorded in other income.

net sales percent change

at actual                            at constant currency rates                         currency rates years ended december 31 (in millions)   2016              2015              2014              2016               2015                2016               2015
renal                                            $3,855            $3,789            $4,172             2    %             (9   )%             5    %              1   %
hospital products                                 6,308             6,179             6,547             2    %             (6   )%             4    %              1   %
total net sales                                 $10,163            $9,968           $10,719             2    %             (7   )%             4    %              1   %
percent change

at actual                            at constant currency rates                         currency rates years ended december 31 (in millions)   2016              2015              2014              2016               2015                 2016               2015
united states                                    $4,259            $4,001            $3,999             6    %        0          %              6    %              0   %
international                                     5,904             5,967             6,720            (1   )%             (11   )%             3    %              2   %
total net sales                                 $10,163            $9,968           $10,719             2    %              (7   )%             4    %              1   %
net sales for the year ended december 31, 2016 increased 2% at actual currency rates and 4% on a constant currency basis. net sales for the year ended december 31, 2015 decreased 7% at actual currency rates but increased 1% on a constant currency basis.
22
foreign currency unfavorably impacted net sales by two percentage points during 2016 compared to the prior year principally due to the strengthening of the u.s. dollar relative to the british pound, mexican peso, colombian peso and the chinese yuan, as well as other currencies, partially offset by the weakening of the u.s. dollar relative to the japanese yen. foreign currency unfavorably impacted net sales by eight percentage points during 2015 compared to 2014 principally due to the strengthening of the u.s. dollar relative to the euro, australian dollar, colombian peso, and certain other currencies.
the comparisons presented at constant currency rates reflect comparative local currency sales at the prior year's foreign exchange rates. this measure provides information on the change in net sales assuming that foreign currency exchange rates had not changed between the prior and the current period. the company believes that the non-gaap measure of change in net sales at constant currency rates, when used in conjunction with the gaap measure of change in net sales at actual currency rates, may provide a more complete understanding of the company's operations and can facilitate a fuller analysis of the company's results of operations, particularly in evaluating performance from one period to another.
franchise net sales reporting the renal segment includes sales of the company's peritoneal dialysis (pd), hemodialysis (hd) and continuous renal replacement therapies (crrt) and additional dialysis services.
the hospital products segment includes four commercial franchises: fluid systems, integrated pharmacy solutions, surgical care and other.
   fluid systems includes sales of the company's iv therapies, infusion pumps and administration sets.

   integrated pharmacy solutions includes sales of the company's premixed and oncology drug platforms, nutrition products and pharmacy compounding services.

   surgical care includes sales of the company's inhaled anesthesia and critical care products as well as biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.

   other includes sales primarily from the company's pharmaceutical partnering business.

the following is a summary of net sales by commercial franchise.
percent change

at actual                            at constant currency rates                         currency rates years ended december 31 (in millions)   2016              2015              2014              2016               2015                 2016               2015
total renal net sales                            $3,855            $3,789            $4,172             2    %              (9   )%             5    %              1    %
fluid systems                                    $2,300            $2,106            $2,129             9    %              (1   )%            11    %              6    %
integrated pharmacy solutions                     2,245             2,297             2,535            (2   )%              (9   )%             0    %             (2   )%
surgical care                                     1,321             1,323             1,373             0    %              (4   )%             1    %              3    %
other                                               442               453               510            (2   )%             (11   )%            (2   )%             (5   )%
total hospital products net sales                $6,308            $6,179            $6,547             2    %              (6   )%             4    %              1    %
net sales in the renal segment increased 2% in 2016 from 2015 but decreased 9% in 2015 from 2014. these amounts include an unfavorable foreign currency impact of three percentage points in 2016 and 10 percentage points in 2015.  sales increased 5% on a constant currency basis in 2016, driven by continued global growth of patients, new product launches and improved pricing in the united states in our pd business. pd contributed approximately two percentage  points to the growth rate during 2016.  in addition, increased sales of the company's crrt to treat acute kidney injury contributed two percentage points to the growth rate during 2016.  renal net sales are expected to be negatively impacted in 2017 by approximately $50 million as compared to 2016 due to certain international strategic market exits.  sales increased 1% on a constant currency basis in 2015, driven by continued growth in the number of pd patients globally, which contributed approximately three percentage points, and strong demand in the acute business. these factors were partially offset by lower sales in the chronic in-center hd business, resulting from the decision to forgo certain lower margin sales opportunities, increased austerity measures in western europe, and competitive pressures for dialyzers.
23
net sales in the hospital products segment increased 2% in 2016 and decreased 6% in 2015. foreign currencies had an unfavorable impact of two percentage points in 2016 and seven percentage points in 2015. hospital products net sales are expected to be negatively impacted in 2017 by approximately $50 million as compared to 2016 due to certain international strategic market exits.  excluding the impact of foreign currency, the principal drivers impacting 2016 net sales growth were the following:
   in the fluid systems franchise, sales increased 11% in 2016 on a constant currency basis driven by favorable pricing and volume for iv solutions and increased sales of the sigma spectrum pump and the related sets in the united states. sales increased 6% in 2015 on a constant currency basis driven by increased sales of infusion system products, which contributed approximately four percentage points, including the relaunch of the sigma spectrum infusion pump in the united states, puerto rico, and canada during 2015. additionally, sales growth in 2015 was impacted by favorable pricing and volume in the united states for the company's iv therapies, which contributed approximately one percentage point.

   in the integrated pharmacy solutions franchise, sales were flat in 2016 on a constant currency basis driven by global demand for the company's nutritional therapies, contributing approximately one percentage point during 2016 and demand for the company's international pharmacy compounding services which contributed approximately one percentage point during 2016. these increases were offset by lower u.s. sales of the company's pharmacy injectable products, as there were government protopam orders in 2015 that did not reoccur in 2016, contributing approximately one percentage point of decline. in addition, u.s. sales of cyclophosphamide, a generic oncology drug, were approximately $210 million and $270 million in 2016 and 2015, respectively, which contributed an approximate three percentage point of decline in 2016. the company expects a significant decline in u.s sales for cyclophosphamide in 2017 due to additional competition in the market. sales decreased 2% in 2015 on a constant currency basis driven by decreased sales of cyclophosphamide, following a competitor entering the u.s. market in november 2014 which contributed approximately six percentage points. u.s. sales of cyclophosphamide during 2014 were approximately $450 million. this decline was offset by an increase in revenues from pharmacy compounding services, increased demand for the company's nutritional therapies, and pharmacy injectable products, including approximately $40 million in sales of protopam, which contributed two percentage points.

   in the surgical care franchise, sales increased 1% in 2016 on a constant currency basis driven by increased demand for international anesthesia products. sales increased 3% in 2015 on a constant currency basis driven by strong global demand for the company's portfolio of anesthetics products, which contributed three percentage points, offset partially by lower sales of select non-core biosurgery products.

   in the other franchise, sales decreased 2% in 2016 on a constant currency basis compared to 2015 driven by lower demand for products manufactured by baxter on behalf of one of its pharmaceutical partners. the company also recognized revenue of $39 million in 2016 as compared to $37 million in 2015 related to the company's manufacturing and supply agreement with baxalta. sales decreased 5% in 2015 on a constant currency basis compared to 2014 driven by one of the company's pharmaceutical partners electing to self-manufacture products previously contract manufactured by baxter. this loss of revenue was partially offset by increased sales related to the company's manufacturing and supply agreement with baxalta.

gross margin and expense ratios change

years ended december 31 (as a percent of net sales)   2016              2015              2014              2016             2015
gross margin                                                 40.4   %          41.6   %          42.7   %        (1.2 pts)        (1.1 pts)
marketing and administrative expenses                        27.0   %          31.0   %          30.9   %        (4.0 pts)          0.1 pts gross margin the special items previously identified in the above had an unfavorable impact of 3.5, 1.7 and 2.1 percentage points on the gross margin ratio in 2016, 2015 and 2014, respectively. refer to the special items section above for additional detail.
excluding the impact of the special items, the gross margin ratio increased 0.6 percentage points in 2016. the gross margin ratio was impacted by a positive sales mix, improved pricing in select areas of the portfolio and favorable manufacturing performance, offset by reduced sales of cyclophosphamide in the united states and foreign exchange.
excluding the impact of the special items, the gross margin ratio in 2015 was unfavorably impacted by decreased sales of cyclophosphamide in the united states, partially offset by an improved product mix in the renal segment.
24
marketing and administrative expenses the special items identified above had an unfavorable impact of 2.3, 2.6 and 1.2 percentage points on the marketing and administrative expenses ratio in 2016, 2015 and 2014, respectively. refer to the special items section above for additional detail.
excluding the impact of the special items, the marketing and administrative expense ratio decreased 3.7 percentage points in 2016 and was impacted by reduced pension expense, as well as benefits from the company's actions taken to rebase its cost structure and continued focus on expense management, in addition to a reduction to expense under the transition services agreement with baxalta.
excluding the impact of the special items, the marketing and administrative expense ratio in 2015 was impacted by the benefits from the company's business optimization actions as the company resets its cost structure, reduced its discretionary spending, and benefited from certain costs charged to baxalta under the transition services agreement. these benefits were partially offset by increased bad debt expense in emerging markets.
pension and other postemployment benefit plan expense expense related to the company's pension and other postemployment benefit plans decreased $111 million in 2016 primarily due to a change in approach to estimating employer service and interest costs and a $706 million voluntary, non-cash contribution to the us qualified plan using retained shares. pension and other postemployment benefit plan expense increased $8 million in 2015 primarily due to a decrease in the discount rate.
business optimization items beginning in the second half of 2015, the company has initiated actions to transform the company's cost structure and enhance operational efficiency. these efforts include restructuring the organization, optimizing the manufacturing footprint, r&d operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. through december 31, 2016 the company incurred cumulative pretax costs of $407 million related to these actions. the costs consisted primarily of employee termination costs, implementation costs, and accelerated depreciation. the company expects to incur additional pretax costs of approximately $390 million and capital expenditures of $90 million related to these initiatives by the end of 2018. these costs will primarily include employee termination costs, implementation costs, and accelerated depreciation. the company expects that approximately 10 percent of the charges will be non-cash. these actions in the aggregate are expected to provide future annual pretax savings of approximately $860 million. the savings from these actions will impact cost of sales, marketing and administrative expenses, and r&d expenses. the company estimates that actions taken through december 31, 2016 have resulted in approximately $343 million of savings in 2016. approximately 85 percent of the expected annual pretax savings are expected to be realized by the end of 2018, with the remainder by the end of 2020.
in addition to the programs above, the company recorded additional net business optimization charges of $125 million in 2016. these charges primarily include employee termination costs, contract termination costs, asset impairments, and gambro integration costs.  approximately 40% of these costs were non-cash. the company does not anticipate incurring any additional costs related to these programs in the future. the actions in the aggregate are expected to provide future annual pretax savings of approximately $19 million. the savings from these actions will impact cost of sales, marketing and administrative expenses, and r&d expenses. the company estimates that the actions taken through december 31, 2016, have resulted in approximately $8 million of savings in the current period. the remaining pretax savings are expected to be realized as the programs are substantially completed by the end of 2017.
refer to note 7 in item 8 for additional information regarding the company's business optimization initiatives.
research and development percent change

years ended december 31 (in millions)   2016              2015              2014              2016                 2015
research and development expenses              $647              $603              $610                   7    %               (1   )%
as a percent of net sales                       6.4   %           6.0   %           5.7   %         0.4 pts               0.3 pts the special items identified above had an unfavorable impact of $80 million, $14 million and $2 million in 2016, 2015 and 2014, respectively.
25
excluding the impact of special items, r&d expenses decreased 4% in 2016 primarily due to the optimization of the infrastructure, the exit of certain programs and the impact of foreign currency. r&d expenses in 2015 declined as the company worked to balance increased investments with efforts to optimize its overall r&d expenditures.
net interest expense net interest expense was $66 million, $126 million and $145 million in 2016, 2015 and 2014, respectively. the decrease in 2016 was principally driven by lower outstanding debt as a result of the first quarter 2016 debt-for-equity exchanges and reduced coupon rates resulting from the third quarter 2016 debt issuance, partially offset by lower capitalized interest compared to 2015. the decrease in 2015 was principally driven by the debt tender offer completed in july 2015 and the maturity of $600 million of 4.625% senior unsecured notes in march 2015, partially offset by higher interest on the company's short term revolving credit facility, lower capitalized interest, and lower income from interest rate hedging activities. refer to note 3 in item 8 for a summary of the components of net interest expense for 2016, 2015 and 2014.
other (income) expense, net other (income) expense, net was income of $4.3 billion in 2016, income of $105 million in 2015 and expense of $21 million in 2014. current year results included net realized gains of $4.4 billion on the retained shares transactions, dividend income of $16 million from the retained shares, and $28 million of income related to foreign currency fluctuations principally relating to intercompany receivables, payables and monetary assets denominated in a foreign currency. these income items were partially offset by net debt extinguishment losses of $153 million. the 2015 results were driven primarily by $52 million of income related to a favorable litigation settlement, $38 million income from the sale of available-for-sale securities, and $113 million of income related to foreign currency fluctuations principally relating to intercompany receivables, payables and monetary assets denominated in a foreign currency, partially offset by a $130 million loss on extinguishment of debt related to the july 2015 debt tender offer.
segment ebitda the company uses income from continuing operations before net interest expense, income tax expense, depreciation and amortization expense (segment ebitda), on a segment basis to make resource allocation decisions and assess the ongoing performance of the company's business segments. refer to note 17 in item 8 for additional details regarding the company's segments. the following is a summary of significant factors impacting the segments' financial results.
renal segment ebitda was $703 million, $566 million and $666 million in 2016, 2015 and 2014, respectively. the increase in 2016 was primarily driven by increased sales and lower marketing and administrative expenses as cost savings were realized from the company's business optimization programs and continued focus on expense management. this was partially offset by unfavorable foreign currency fluctuations, incremental manufacturing and quality costs, and higher allocated r&d costs. ebitda declined in 2015 due to unfavorable foreign currency fluctuations, the impairment of certain intangible assets and investments in certain quality programs and manufacturing capabilities, partially offset by efficiencies related to the integration of the gambro business.
hospital products segment ebitda was $2.3 billion, $2.0 billion and $2.2 billion in 2016, 2015 and 2014, respectively. the increase in 2016 was driven by increased sales, favorable manufacturing performance, lower allocated r&d costs, and lower marketing and administrative expenses as cost savings were realized from the company's business optimization programs and continued focus on expense management. this growth was partially offset by unfavorable foreign currency fluctuations. ebitda in 2015 was impacted primarily by unfavorable foreign currency fluctuations and decreased sales of the higher margin cyclophosphamide product. this was offset by a reduction in costs in 2014 related to manufacturing inefficiencies and quality costs.
corporate and other certain income and expense amounts are not allocated to a segment. these amounts are detailed in the table in note 17 in item 8 and primarily include net interest expense, foreign exchange fluctuations (principally relating to intercompany receivables, payables and loans denominated in foreign currency), the majority of the foreign currency hedging activities, corporate headquarters costs, international global support costs, stock compensation expense, non-strategic investments and related income and expense, certain employee benefit plan costs as well as certain nonrecurring gains, losses, and other charges (such as business optimization and asset impairments).
26
income taxes effective income tax rate the effective income tax rate for continuing operations was (0.2%) in 2016, 8.2% in 2015 and 6.7% in 2014. the company anticipates that the effective income tax rate from continuing operations, calculated in accordance with gaap, will be approximately 21.5% in 2017, excluding any impact from tax windfalls or deficiencies attributable to stock compensation exercises as well as additional audit developments or other special items.
the company's effective tax rate differs from the u.s. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes and foreign taxes that are different than the u.s. federal statutory rate. the average foreign effective tax rate on international pre-tax income from continuing operations was 25.2%, 27.5% and 24.1% for the years ended december 31, 2016, 2015 and 2014, respectively. the company's average foreign effective tax rate was lower than the u.s. federal statutory rate as a result of the impact of tax incentives in puerto rico, switzerland and certain other tax jurisdictions outside of the united states, as well as foreign earnings in tax jurisdictions with lower statutory rates than the united states. adversely impacting the foreign rate were foreign loss-generating operations that did not receive tax benefits due to the losses resulting in, or contributing to, the need for a valuation allowance. in addition, as discussed further below, the company's effective income tax rate can be impacted in each year by discrete factors or events. refer to note 15 in item 8 for further information regarding the company's income taxes.
factors impacting the company's effective tax rate in 2016 included tax-free net realized gains during the first and second quarter associated with the exchanges of baxalta retained shares for the company's debt and the company's shares as well as tax-free net realized gains associated with the contribution of baxalta retained shares to the company's pension plan. additionally, the income tax rate for 2016 was favorably impacted by tax benefits from partially settling an irs (2008-2013) income tax audit, settling a german (2008-2011) income tax audit, resolution of uncertain tax positions related to the company's turkish joint venture, other transfer pricing matters, and partial settlement of interest expense deductions related to the company's acquisition of gambro.
factors adversely impacting the company's effective tax rate in 2015 included charges related to contingent tax matters primarily related to transfer pricing and the separation of baxalta as well as the need to record valuation allowances for some loss making entities. partially offsetting the foregoing adverse factors was a benefit from reaching a settlement of a puerto rico excise tax matter as well as the u.s. r&d credit resulting from the retroactive reinstatement in december 2015 of the protecting americans from tax hikes act of 2015.
factors impacting the company's effective tax rate in 2014 included the favorable settlement of a portion of the company's contingent tax matter related to operations in turkey as well as a favorable shift of earnings from high to low tax jurisdictions compared to the prior period. additionally, the effective tax rate was unfavorably impacted by increases in valuation allowances due to the tax benefit from losses that the company does not believe that it is more likely than not to realize and interest expense related to the company's unrecognized tax benefits.
the company earns a significant amount of its operating income outside the united states, of which a substantial portion is deemed to be indefinitely reinvested in foreign jurisdictions. as a result, most of the company's cash and short-term investments are held by foreign subsidiaries. the company does not intend or foresee a need to repatriate these funds and expects existing domestic cash and short-term investments and cash flows from operations to continue to be sufficient to fund domestic operating activities and cash commitments for investing and financing activities, such as regular quarterly dividends and capital expenditures, for at least the next 12 months and thereafter for the foreseeable future.
if the company should require more capital in the united states than is generated by its domestic operations (e.g,. to fund significant discretionary activities such as business acquisitions and share repurchases), the company could elect to repatriate future earnings from foreign jurisdictions or raise capital in the united states through debt or equity issuances. these alternatives could result in higher effective tax rates, increased interest expense or dilution of the company's earnings. the company has borrowed domestically and continues to believe it has the ability to do so at reasonable interest rates.
income from continuing operations and earnings per diluted share income from continuing operations was $5.0 billion in 2016, $393 million in 2015 and $457 million in 2014. income from continuing operations per diluted share was $9.01 in 2016, $0.72 in 2015 and $0.83 in 2014. the significant factors and events causing the net changes from 2015 to 2016 and 2014 to 2015 are discussed above. additionally, income from continuing operations per diluted share was positively impacted by the repurchase of 17.8 million shares through cash repurchases and an equity-for-equity exchange of retained shares for outstanding baxter shares in 2016, and the repurchase of eight million shares in 2014. refer to note 12 in item 8 for further information regarding the company's stock repurchases.
27
(loss) income from discontinued operations the following table is a summary of the operating results of baxalta, which have been reflected as discontinued operations for the years ended december 31, 2016, 2015 and 2014.
years ended december 31 (in millions)                    2016                2015             2014

net sales                                                                $148              $2,895            $6,523
(loss) income from discontinued operations before income taxes            (10   )             752             2,562
gain on disposal of discontinued operations                                19                   -                 -
income tax expense                                                         10                 177               522
total (loss) income from discontinued operations                          $(1   )            $575            $2,040
refer to note 2 in item 8 for additional information regarding the separation of baxalta.
liquidity and capital resources the company's cash flows reflect both continuing and discontinued operations.
cash flows from operations - continuing operations operating cash flows from continuing operations totaled $1.6 billion in 2016, $1.3 billion in 2015 and $1.2 billion in 2014. the cash flows from continuing operations in 2015 were impacted by the receipt of a $52 million legal settlement as well as $114 million of payments related to the july 2015 debt tender offer. see below for other factors impacting the increase in cash flows in 2016 and the decrease in cash flows in 2015.
accounts receivable cash flows relating to accounts receivable increased in 2016 and 2015 as the days sales outstanding decreased in 2016 and increased in 2015. days sales outstanding were 54.5 days, 56.2 days and 54.2 days for 2016, 2015 and 2014, respectively. days sales outstanding decreased in 2016 primarily driven by timing of collections in certain international markets. days sales outstanding increased in 2015 driven by slower collections in the united states.
inventories cash flows relating to inventory improved from an outflow of $118 million in 2015 to an inflow of $80 million in 2016, driven by continued working capital improvement initiatives which decreased days inventory on hand by ten days and increased turns significantly as compared to the prior year. the following is a summary of inventories at december 31, 2016 and 2015, as well as inventory turns by segment for 2016, 2015 and 2014. inventory turns for the year are calculated as the annualized fourth quarter cost of sales divided by the year-end inventory balance.
inventories                           inventory turns

(in millions, except inventory turn data)   2016                2015            2016            2015            2014
renal                                                $544                $605         4.4             3.7             3.6
hospital products                                     885                 955         3.9             3.6             3.7
other                                                   1                  44         n/a             n/a             n/a total company                                      $1,430              $1,604         4.1             3.6             3.7
other the changes in accounts payable and accrued liabilities were an outflow of $197 million in 2016, an inflow of $236 million in 2015 and a $37 million outflow in 2014. the change in 2016 was primarily driven by an increase in tax payments primarily due to a tax settlement as well as the timing of payments to suppliers. refer to note 15 in item 8 for additional details regarding the tax settlement. the change in 2015 was primarily driven by the timing of payments to suppliers as well as the timing of tax payments.
payments related to the execution of the sigma spectrum infusion pump recalls as well as the company's business optimization initiatives were $191 million in 2016, $112 million in 2015 and $124 million in 2014. refer to note 7 in item 8 for further information regarding the sigma spectrum infusion pump recalls and the business optimization initiatives.
28
other balance sheet items had net cash inflows of $115 million in 2016, and outflows of $341 million and $17 million in 2015 and 2014, respectively. in 2016, the company received a u.s. federal income tax refund of $250 million as a result of carrying back to prior tax years the company's 2015 u.s. tax loss which arose, in significant part, from the funding of the company's defined benefit pension plan with a portion of the baxalta retained stake. additionally, cash contributions to the company's pension plans totaled $66 million, $157 million and $74 million in 2016, 2015 and 2014, respectively. the changes during 2015 and 2014 were primarily driven by prepaid expenses and hedging activity.
cash flows from investing activities - continuing operations capital expenditures capital expenditures relating to continuing operations totaled $719 million in 2016, $911 million in 2015 and $925 million in 2014. the company's capital expenditures in 2016 and 2015 consisted of targeted investments in projects to support production of pd and iv solutions as well as expansion activities for dialyzers. the decline in capital expenditures over the three years was due to a reduction in spending related to ongoing projects and the completion of certain expansion activities.
acquisitions and investments net cash outflows related to acquisitions and investments were $48 million in 2016, $34 million in 2015 and $95 million in 2014. the cash outflows in 2016 were driven primarily by the acquisition of the rights to vancomycin from celerity. the cash outflows in 2015 were driven by the acquisition of the rights to cefazolin injection in galaxy container (2g/100ml) from celerity. the cash outflows in 2014 were driven by the acquisitions of ic net international ltd and certain investments.
refer to note 5 in item 8 for further information about the company's significant acquisitions and other arrangements.
divestitures and other investing activities net cash inflows relating to divestitures and other investing activities were $37 million in 2016, $84 million in 2015 and $99 million in 2014. the decrease from 2015 to 2016 was primarily driven by the sale of certain investments and other assets in 2015. cash inflows in 2014 primarily related to proceeds from the divestiture of baxter's legacy crrt business and the sale of certain investments.
cash flows from financing activities debt issuances, net of payments of obligations net cash outflows related to debt and other financing obligations totaled $56 million in 2016 primarily related to a $190 million repayment of the company's 0.95% senior unsecured notes that matured in june 2016, a $130 million repayment of the company's 5.9% senior unsecured notes that matured in september 2016 and the redemption of approximately $1 billion in aggregate principal amount of senior notes in september 2016, as well as the repayment of other short-term obligations. the company also had $300 million of net repayments related to its commercial paper program. these cash outflows were partially offset by issuances of debt totaling $1.6 billion of senior notes in august 2016. refer to note 8 in item 8 for additional details regarding the debt transactions in 2016.
net cash inflows related to debt and other financing obligations totaled $2.4 billion in 2015 driven by approximately $6.9 billion in issuances of debt primarily related to the baxalta senior notes and borrowings under the company's revolving credit facilities. the company purchased an aggregate of approximately $2.7 billion in principal amount of its notes in 2015. additionally, the company repaid $600 million of 4.625% senior unsecured notes that matured in march 2015 and borrowings under the company's euro-denominated revolving credit facility. the company issued and redeemed commercial paper throughout the year, and had $300 million outstanding as of december 31, 2015.
net cash outflows related to debt and other financing obligations totaled $113 million in 2014 driven by approximately $1 billion in repayments, which included $500 million of floating rate senior unsecured notes that matured in december 2014 as well as $350 million of 4.0% senior unsecured notes that matured in march 2014. the company issued and redeemed commercial paper throughout the year, and had $875 million outstanding as of december 31, 2014.
the company's debt instruments discussed above are unsecured and contain certain covenants, including restrictions relating to the company's issuance of secured debt.
29
other financing activities in connection with the separation, baxter transferred $2.1 billion of cash to baxalta in 2015.
cash dividend payments totaled $0.3 billion in 2016, $0.9 billion in 2015 and $1.1 billion in 2014. the decrease in cash dividend payments in 2016 and 2015 was primarily due to the decrease of the quarterly dividend after the separation of baxalta, from $0.52 per share for quarterly dividends beginning after may 2014 to $0.115 per quarterly dividends beginning after july 2015. the baxter cash dividend was increased to $0.13 per share for quarterly dividends beginning after may 2016.
proceeds and realized excess tax benefits from stock issued under employee benefit plans totaled $325 million, $200 million and $369 million in 2016, 2015 and 2014, respectively. total realized excess tax benefits, which were $39 million in 2016, $7 million in 2015 and $24 million in 2014, are presented in the consolidated statements of cash flows as an inflow in the financing section and an outflow in the operating section.
in 2016, the company executed an equity-for-equity exchange of retained shares for 11.5 million outstanding baxter shares. as authorized by the board of directors, the company repurchases its stock depending on the company's cash flows, net debt level and market conditions. in july 2012, the board of directors authorized the repurchase of up to $2.0 billion of the company's common stock. the board of directors increased this authority by an additional $1.5 billion in november 2016. the company paid $287 million in cash to repurchase approximately 6.3 million shares pursuant to this authority in 2016 and had $1.7 billion remaining available under this authorization as of december 31, 2016. the company did not repurchase any stock during 2015.
credit facilities, access to capital and credit ratings credit facilities as of december 31, 2016, the company's u.s. dollar-denominated revolving credit facility and euro-denominated senior revolving credit facility had a maximum capacity of $1.5 billion and approximately 200 million, respectively. as of december 31, 2016, the company was in compliance with the financial covenants in these agreements. the non-performance of any financial institution supporting either of the credit facilities would reduce the maximum capacity of these facilities by each institution's respective commitment.
effective july 1, 2015, the company terminated its $1.5 billion u.s. dollar-denominated revolving credit facility and 300 million euro-denominated revolving credit facility, which were set to mature in december 2015, in connection with the separation and distribution. in connection with such terminations, the company entered into credit agreements providing for a senior u.s. dollar-denominated revolving credit facility in an aggregate principal amount of up to $1.5 billion maturing in 2020, as well as a euro-denominated senior revolving credit facility in an aggregate principal amount of up to 200 million maturing in 2020. the company may, at its option, seek to increase the aggregate commitment under the new u.s. facility by up to an additional $750 million. the new facilities enable the company to borrow funds on an unsecured basis at variable interest rates, and contain various covenants, including a maximum net leverage ratio and maximum interest coverage ratio.
additionally, as of december 31, 2015, the company had a third revolving credit facility, with a maximum capacity of $1.8 billion, which was scheduled to mature on the earlier of march 28, 2016 and the date on which commitments under the facility have been reduced to zero or terminated in whole pursuant to the terms thereof. on january 27, 2016, baxter exchanged all 37.6 million shares of baxalta common stock for the $1.45 billion aggregate principal amount outstanding under this revolving credit facility. this exchange extinguished all outstanding indebtedness under the facility, at which time the facility was terminated. in connection with the exchange of baxalta common stock, baxter recognized $1.2 billion of realized gains in 2016.
the company also maintains other credit arrangements, as described in note 8 in item 8.
access to capital the company intends to fund short-term and long-term obligations as they mature through cash on hand, future cash flows from operations or by issuing additional debt. the company had $2.8 billion of cash and equivalents as of december 31, 2016, with adequate cash available to meet operating requirements in each jurisdiction in which the company operates. the company invests its excess cash in certificates of deposit and money market funds, and diversifies the concentration of cash among different financial institutions.
the company's ability to generate cash flows from operations, issue debt or enter into other financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for the company's products or in the solvency of its
30
customers or suppliers, deterioration in the company's key financial ratios or credit ratings or other significantly unfavorable changes in conditions. however, the company believes it has sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support the company's growth objectives.
the company continues to do business with foreign governments in certain countries, including greece, spain, portugal and italy, which have experienced deterioration in credit and economic conditions. as of december 31, 2016, the company's net accounts receivable from the public sector in greece, spain, portugal and italy totaled $137 million.
while these economic conditions have not significantly impacted the company's ability to collect receivables, global economic conditions and liquidity issues in certain countries have resulted, and may continue to result, in delays in the collection of receivables and credit losses.
credit ratings the company's credit ratings at december 31, 2016 were as follows:
standard &amp; poor's   fitch    moody's

ratings senior debt       a-                      bbb+     baa2
short-term debt   a2                      f2       p2
outlook           stable                  stable   stable contractual obligations as of december 31, 2016, the company had contractual obligations, excluding accounts payable and accrued liabilities, payable or maturing in the following periods.
(in millions)                                     total       less than        one to         three to       more than one year     three years      five years      five years

long-term debt and capital lease obligations, including current maturities        $2,794            $3              $6            $700          $2,085
interest on short- and long-term debt and capital lease obligations 1              1,496            84             169             163           1,080
operating leases                                                                     663           129             193             125             216
other long-term liabilities2                                                         443             -             114              43             286
purchase obligations3                                                                450           275             153              20               2
contractual obligations4                                                          $5,846          $491            $635          $1,051          $3,669
1   interest payments on debt and capital lease obligations are calculated for future periods using interest rates in effect at the end of 2016. projected interest payments include the related effects of interest rate swap agreements. certain of these projected interest payments may differ in the future based on changes in floating interest rates, foreign currency fluctuations or other factors or events. the projected interest payments only pertain to obligations and agreements outstanding at december 31, 2016. refer to note 8 and note 9 in item 8 for further discussion regarding the company's debt instruments and related interest rate agreements outstanding at december 31, 2016.

2   the primary components of other long-term liabilities in the company's consolidated balance sheet are liabilities relating to pension and other postemployment benefit plans, litigation, and foreign currency hedges. the company projected the timing of the future cash payments based on contractual maturity dates (where applicable) and estimates of the timing of payments (for liabilities with no contractual maturity dates). the actual timing of payments could differ from the estimates.

the company contributed $772 million, $157 million and $74 million to its defined benefit pension plans in 2016, 2015 and 2014, respectively. the timing of funding in the future is uncertain and is dependent on future movements in interest rates and investment returns, changes in laws and regulations, and other variables. therefore, the table above excludes pension plan cash outflows. the pension plan balance included in other long-term liabilities (and excluded from the table above) totaled $1.5 billion at december 31, 2016.
3   includes the company's significant contractual unconditional purchase obligations. for cancelable agreements, any penalty due upon cancellation is included. these commitments do not exceed the company's projected requirements and are in the normal course of business. examples include firm commitments for raw material purchases, utility agreements and service contracts.

31
4   excludes contingent liabilities and uncertain tax positions. these amounts have been excluded from the contractual obligations above due to uncertainty regarding the timing and amount of future payments. refer to notes 10 and 11 in item 8 for additional information regarding these commitments.

off-balance sheet arrangements baxter periodically enters into off-balance sheet arrangements. certain contingencies arise in the normal course of business, and are not recorded in the consolidated balance sheet in accordance with gaap (such as contingent joint development and commercialization arrangement payments). also, upon resolution of uncertainties, the company may incur charges in excess of presently established liabilities for certain matters (such as contractual indemnifications). for a discussion of the company's significant off-balance sheet arrangements, refer to note 10 in item 8 for information regarding receivable securitizations, note 11 in item 8 regarding joint development and commercialization arrangements and indemnifications, and note 16 in item 8 regarding legal contingencies.
financial instrument market risk the company operates on a global basis and is exposed to the risk that its earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. the company's hedging policy attempts to manage these risks to an acceptable level based on the company's judgment of the appropriate trade-off between risk, opportunity and costs. refer to note 9 and note 10 in item 8 for further information regarding the company's financial instruments and hedging strategies.
currency risk the company is primarily exposed to foreign exchange risk with respect to revenues generated outside of the united states denominated in the euro, british pound, chinese yuan, korean won, australian dollar, canadian dollar, japanese yen, colombian peso, brazilian real, swedish krona, mexican peso, and new zealand dollar. the company manages its foreign currency exposures on a consolidated basis, which allows the company to net exposures and take advantage of any natural offsets. in addition, the company uses derivative and nonderivative financial instruments to further reduce the net exposure to foreign exchange. gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and stockholders' equity volatility relating to foreign exchange. financial market and currency volatility may limit the company's ability to cost-effectively hedge these exposures.
the company may use options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions denominated in foreign currencies and recognized assets and liabilities. the maximum term over which the company has cash flow hedge contracts in place related to forecasted transactions at december 31, 2016 is 12 months. the company also enters into derivative instruments to hedge certain intercompany and third-party receivables and payables and debt denominated in foreign currencies.
currency restrictions enacted in venezuela require baxter to obtain approval from the venezuelan government to exchange venezuelan bolivars for u.s. dollars and require such exchange to be made at the official exchange rate established by the government. in the first quarter of 2016, the venezuelan government moved from the three-tier exchange rate system to a two-tiered exchange rate system and the official rate for food and medicine imports was adjusted from 6.3 to 10 bolivars per u.s. dollar.  this devaluation resulted in a charge of $9 million during the first quarter of 2016. as of december 31, 2016, the company's exposure to venezuelan operations was approximately $12 million.
as part of its risk-management program, the company performs sensitivity analyses to assess potential changes in the fair value of its foreign exchange instruments relating to hypothetical and reasonably possible near-term movements in foreign exchange rates.
a sensitivity analysis of changes in the fair value of foreign exchange option and forward contracts outstanding at december 31, 2016, while not predictive in nature, indicated that if the u.s. dollar uniformly weakened by 10% against all currencies, on a net-of-tax basis, the net asset balance of $13 million with respect to those contracts would decrease by $34 million, resulting in a net liability position. a similar analysis performed with respect to option and forward contracts outstanding at december 31, 2015 indicated that, on a net-of-tax basis, the net asset balance of $5 million would decrease by $17 million.
the sensitivity analysis model recalculates the fair value of the foreign exchange option and forward contracts outstanding at december 31, 2016 by replacing the actual exchange rates at december 31, 2016 with exchange rates that are 10% weaker compared to the actual exchange rates for each applicable currency. all other factors are held constant. these sensitivity analyses disregard the possibility that currency exchange rates can move in opposite directions and that gains from one currency may or may not be offset by
32
losses from another currency. the analyses also disregard the offsetting change in value of the underlying hedged transactions and balances.
interest rate and other risks the company is also exposed to the risk that its earnings and cash flows could be adversely impacted by fluctuations in interest rates. the company's policy is to manage interest costs using a mix of fixed- and floating-rate debt that the company believes is appropriate. to manage this mix in a cost-efficient manner, the company periodically enters into interest rate swaps in which the company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. the company also periodically uses forward-starting interest rate swaps and treasury rate locks to hedge the risk to earnings associated with fluctuations in interest rates relating to anticipated issuances of term debt.
as part of its risk management program, the company performs sensitivity analyses to assess potential gains and losses in earnings relating to hypothetical movements in interest rates. a 19 basis-point increase in interest rates (approximately 10% of the company's weighted-average interest rate during 2016) affecting the company's financial instruments, including debt obligations and related derivatives, would have an immaterial effect on the company's 2016, 2015 and 2014 earnings and on the fair value of the company's fixed-rate debt as of the end of each fiscal year.
with respect to the company's investments in affiliates, the company believes any reasonably possible near-term losses in earnings, cash flows and fair values would not be material to the company's consolidated financial position.
changes in accounting standards refer to note 1 in item 8 for information on changes in accounting standards.
critical accounting policies the preparation of financial statements in accordance with gaap requires the company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. a summary of the company's significant accounting policies is included in note 1 in item 8. certain of the company's accounting policies are considered critical because these policies are the most important to the depiction of the company's financial statements and require significant, difficult or complex judgments by the company, often requiring the use of estimates about the effects of matters that are inherently uncertain. actual results that differ from the company's estimates could have an unfavorable effect on the company's results of operations and financial position. the following is a summary of accounting policies that the company considers critical to the consolidated financial statements.
revenue recognition and related provisions and allowances the company's policy is to recognize revenues from product sales and services when earned. specifically, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. for product sales, revenue is not recognized until title and risk of loss have transferred to the customer. the shipping terms for the majority of the company's revenue arrangements are fob destination. the company sometimes enters into arrangements in which it commits to delivering multiple products or services to its customers. in these cases, total arrangement consideration is allocated to the deliverables based on their relative selling prices. then the allocated consideration is recognized as revenue in accordance with the principles described above. selling prices are determined by applying a selling price hierarchy. selling prices are determined using vendor specific objective evidence (vsoe), if it exists. otherwise, selling prices are determined using third party evidence (tpe). if neither vsoe nor tpe is available, the company uses its best estimate of selling prices.
provisions for rebates, chargebacks to wholesalers and distributors, returns, and discounts (collectively, "sales deductions") are provided for at the time the related sales are recorded, and are reflected as a reduction of sales. the sales deductions are based primarily on estimates of the amounts earned or that will be claimed on such sales.
the company periodically and systematically evaluates the collectability of accounts receivable and determines the appropriate reserve for doubtful accounts. in determining the amount of the reserve, the company considers historical credit losses, the past-due status of receivables, payment history and other customer-specific information, and any other relevant factors or considerations.
the company also provides for the estimated costs that may be incurred under its warranty programs when the cost is both probable and reasonably estimable, which is at the time the related revenue is recognized. the cost is determined based on actual company experience for the same or similar products as well as other relevant information. estimates of future costs under the company's
33
warranty programs could change based on developments in the future. the company is not able to estimate the probability or amount of any future developments that could impact the reserves, but believes presently established reserves are adequate.
pension and other postemployment benefit (opeb) plans the company provides pension and other postemployment benefits to certain of its employees. these employee benefit expenses are reported in the same line items in the consolidated income statement as the applicable employee's compensation expense. the valuation of the funded status and net periodic benefit cost for the plans is calculated using actuarial assumptions. these assumptions are reviewed annually, and revised if appropriate. the significant assumptions include the following:
   interest rates used to discount pension and opeb plan liabilities;

   the long-term rate of return on pension plan assets;

   rates of increases in employee compensation (used in estimating liabilities);

   anticipated future healthcare trend rates (used in estimating the opeb plan liability); and

   other assumptions involving demographic factors such as retirement, mortality and turnover (used in estimating liabilities).

selecting assumptions involves an analysis of both short-term and long-term historical trends and known economic and market conditions at the time of the valuation (also called the measurement date). the use of different assumptions would result in different measures of the funded status and net cost. actual results in the future could differ from expected results. the company is not able to estimate the probability of actual results differing from expected results, but believes its assumptions are appropriate.
the company's key assumptions are listed in note 13 in item 8. the most critical assumptions relate to the plans covering u.s. and puerto rico employees, because these plans are the most significant to the company's consolidated financial statements.
discount rate assumption effective for the december 31, 2016 measurement date, the company utilized discount rates of 4.09% and 3.89% to measure its benefit obligations for the u.s. and puerto rico pension plans and opeb plan, respectively. the company used a broad population of approximately 200 aa-rated corporate bonds as of december 31, 2016 to determine the discount rate assumption. all bonds were denominated in u.s. dollars, with a minimum amount outstanding of $50 million. this population of bonds was narrowed from a broader universe of approximately 700 moody's aa rated, non-callable (or callable with make-whole provisions) bonds by eliminating the top 10th percentile and bottom 40th percentile to adjust for any pricing anomalies and to represent the bonds baxter would most likely select if it were to actually annuitize its pension and opeb plan liabilities. this portfolio of bonds was used to generate a yield curve and associated spot rate curve to discount the projected benefit payments for the u.s. and puerto rico plans. the discount rate is the single level rate that produces the same result as the spot rate curve.
for plans in canada, japan, the united kingdom and the eurozone, the company uses a method essentially the same as that described for the u.s. and puerto rico plans. for the company's other international plans, the discount rate is generally determined by reviewing country- and region-specific government and corporate bond interest rates.
to understand the impact of changes in discount rates on pension and opeb plan cost, the company performs a sensitivity analysis. holding all other assumptions constant, for each 50 basis point (i.e., one-half of one percent) increase in the discount rate, global pre-tax pension and opeb plan cost would decrease by approximately $36 million, and for each 50 basis point decrease in the discount rate, global pre-tax pension and opeb plan cost would increase by approximately $40 million.
effective january 1, 2016, the company changed its approach used to calculate the service and interest components of net periodic benefit cost. previously, the company calculated the service and interest components utilizing a single weighted-average discount rate derived from the yield curve used to measure the benefit obligation. the company elected an alternative approach that utilizes a full yield curve approach in the estimation of these components by applying the specific spot rates along the yield curve used in the determination of the benefit obligation to their underlying projected cash flows. the company believes this approach provides a more precise measurement of service and interest costs by improving the correlation between projected benefit cash flows and their corresponding spot rates. the company accounted for this change prospectively as a change in estimate. as a result of this change, the service cost and interest cost for these plans was reduced by $40 million in 2016 compared to the previous method.
34
return on plan assets assumption in measuring the net periodic cost for 2016, the company used a long-term expected rate of return of 7.00% for the pension plans covering u.s. and puerto rico employees. this assumption will decrease to 6.50% in 2017. this assumption is not applicable to the company's opeb plan because it is not funded.
the company establishes the long-term asset return assumption based on a review of historical compound average asset returns, both company-specific and relating to the broad market (based on the company's asset allocation), as well as an analysis of current market and economic information and future expectations. the current asset return assumption is supported by historical market experience for both the company's actual and targeted asset allocation. in calculating net pension cost, the expected return on assets is applied to a calculated value of plan assets, which recognizes changes in the fair value of plan assets in a systematic manner over five years. the difference between this expected return and the actual return on plan assets is a component of the total net unrecognized gain or loss and is subject to amortization in the future.
to understand the impact of changes in the expected asset return assumption on net cost, the company performs a sensitivity analysis. holding all other assumptions constant, for each 50 basis point increase (decrease) in the asset return assumption, global pre-tax pension plan cost would decrease (increase) by approximately $22 million.
other assumptions for the u.s. and puerto rico plans, beginning with the december 31, 2014 measurement date, the company used the rp 2014 combined mortality table adjusted to reflect baxter specific past experience with improvements projected using the generational bb-2d projection scale adjusted to a long term improvement of 0.8% in 2027. for all other pension plans, the company utilized country- and region-specific mortality tables to calculate the plans' benefit obligations. the company periodically analyzes and updates its assumptions concerning demographic factors such as retirement, mortality and turnover, considering historical experience as well as anticipated future trends.
the assumptions relating to employee compensation increases and future healthcare costs are based on historical experience, market trends, and anticipated future company actions. refer to note 13 in item 8 for information regarding the sensitivity of the opeb plan obligation and the total of the service and interest cost components of opeb plan cost to potential changes in future healthcare trend rates.
legal contingencies the company is involved in product liability, patent, commercial, regulatory and other legal proceedings that arise in the normal course of business. refer to note 16 in item 8 for further information. the company records a liability when a loss is considered probable and the amount can be reasonably estimated. if the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate, the minimum amount in the range is accrued. if a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. the company has established reserves for certain of its legal matters. at december 31, 2016, total legal liabilities were $53 million.
the company's loss estimates are generally developed in consultation with outside counsel and are based on analyses of potential outcomes. with respect to the recording of any insurance recoveries, after completing the assessment and accounting for the company's legal contingencies, the company separately and independently analyzes its insurance coverage and records any insurance recoveries that are probable of occurring at the gross amount that is expected to be collected. in performing the assessment, the company reviews available information, including historical company-specific and market collection experience for similar claims, current facts and circumstances pertaining to the particular insurance claim, the financial viability of the applicable insurance company or companies, and other relevant information.
while the liability of the company in connection with certain claims cannot be estimated and although the resolution in any reporting period of one or more of these matters could have a significant impact on the company's results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on the company's consolidated financial position. while the company believes it has valid defenses in these matters, litigation is inherently uncertain, excessive verdicts do occur, and the company may in the future incur material judgments or enter into material settlements of claims.
deferred tax asset valuation allowances and reserves for uncertain tax positions the company maintains valuation allowances unless it is more likely than not that all or a portion of the deferred tax asset will be realized. changes in valuation allowances are included in the company's tax provision in the period of change. in determining whether a valuation allowance is warranted, the company evaluates factors such as prior earnings history, expected future earnings, carryback
35
and carryforward periods, and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset. the realizability assessments made at a given balance sheet date are subject to change in the future, particularly if earnings of a subsidiary are significantly higher or lower than expected, or if the company takes operational or tax planning actions that could impact the future taxable earnings of a subsidiary.
in the normal course of business, the company is audited by federal, state and foreign tax authorities, and is periodically challenged regarding the amount of taxes due. these challenges relate to the timing and amount of deductions and the allocation of income among various tax jurisdictions. the company believes its tax positions comply with applicable tax law and the company intends to defend its positions. in evaluating the exposure associated with various tax filing positions, the company records reserves for uncertain tax positions in accordance with gaap, based on the technical support for the positions, the company's past audit experience with similar situations, and potential interest and penalties related to the matters. the company's results of operations and effective tax rate in a given period could be impacted if, upon final resolution with taxing authorities, the company prevailed in positions for which reserves have been established, or was required to pay amounts in excess of established reserves.
valuation of intangible assets, including ipr&d the company acquires intangible assets and records them at fair value. valuations are generally completed for business acquisitions using a discounted cash flow analysis, incorporating the stage of completion and consideration of market participant assumptions. the most significant estimates and assumptions inherent in a discounted cash flow analysis include the amount and timing of projected future cash flows, the discount rate used to measure the risks inherent in the future cash flows, the assessment of the asset's life cycle, and the competitive and other trends impacting the asset, including consideration of technical, legal, regulatory, economic and other factors. each of these factors and assumptions can significantly affect the value of the intangible asset.
acquired in-process r&d (ipr&d) is the value assigned to acquired technology or products under development which have not received regulatory approval and have no alternative future use. acquired ipr&d included in a business combination is capitalized as an indefinite-lived intangible asset. development costs incurred after the acquisition are expensed as incurred. upon receipt of regulatory approval of the related technology or product, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. if the r&d project is abandoned, the indefinite-lived asset is charged to expense.
r&d acquired in transactions that are not business combinations is expensed immediately. for such transactions, payments made to third parties on or after regulatory approval are capitalized and amortized over the remaining useful life of the related asset, and are classified as intangible assets.
due to the inherent uncertainty associated with r&d projects, there is no assurance that actual results will not differ materially from the underlying assumptions used to prepare discounted cash flow analyses, nor that the r&d project will result in a successful commercial product.
impairment of assets goodwill and other indefinite-lived intangible assets are subject to impairment reviews annually, and whenever indicators of impairment exist. the company assesses goodwill for impairment based on its reporting units, which are the same as its operating segments, renal and hospital products. as of december 31, 2016, the date of the company's annual impairment review, the fair value of the company's reporting units were in excess of their carrying values. the company performs a qualitative assessment of other indefinite-lived intangible assets, including ipr&d, at least annually. if the intangible asset is determined to be more likely than not impaired as a result of the assessment, the company completes a quantitative impairment test. intangible assets with definite lives and other long-lived assets (such as fixed assets) are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. refer to note 1 in item 8 for further information. the company's impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future volume, revenue and expense growth rates, changes in working capital use, foreign currency exchange rates, the selection of an appropriate discount rate, asset groupings, and other assumptions and estimates. the estimates and assumptions used are consistent with the company's business plans and when applicable, market participant's views of the company and similar companies. the use of alternative estimates and assumptions could increase or decrease the estimated fair values of the assets, and potentially result in different impacts to the company's results of operations. actual results may differ from the company's estimates.
stock-based compensation plans stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the substantive vesting period. the company's stock compensation costs primarily relate to awards of stock
36
options, restricted stock units (rsus), and performance share units (psus). the company uses the black-scholes model for estimating the fair value of stock options, and significant assumptions include long-term projections regarding stock price volatility, employee exercise, post-vesting termination and pre-vesting forfeiture behaviors, interest rates and dividend yields. the company's expected volatility assumption is based on a weighted-average of the historical volatility of baxter's stock and the implied volatility from traded options on baxter's stock, with historical volatility more heavily weighted. the expected life assumption is primarily based on the vesting terms of the stock option, historical employee exercise patterns and employee post-vesting termination behavior. the risk-free interest rate for the expected life of the option is based on the u.s. treasury yield curve in effect at the time of grant. the dividend yield reflects historical experience as well as future expectations over the expected life of the option.
the fair value of rsus is equal to the quoted price of the company's common stock on the date of grant.
psus granted in 2016 are based either on adjusted operating margin, return on invested capital (roic), or are based upon baxter stock performance relative to the company's peer group. the vesting condition for such psus based on adjusted operating margin or roic have annual performance targets set at the beginning of the year for each tranche of the award during the three-year service period. the holder of the adjusted operating margin or roic psus is entitled to receive a number of shares of common stock equal to a percentage, ranging from 0% to 200%, of the adjusted operating margin or roic psus granted, depending on the actual results compared to the annual performance targets as such results may be adjusted for individual performance. compensation cost for the adjusted operating margin or roic psus is measured based on the fair value of the awards on the date that the specific vesting terms for each tranche of the award are established. the fair value of the awards is determined based on the quoted price of the company's stock on the grant date for each tranche of the award. the compensation cost for adjusted operating margin or roic psus is adjusted at each reporting date to reflect the estimated probability of achieving the adjusted operating margin or roic vesting condition. the probability of achieving the operating margin vesting condition is such that the compensation cost has been adjusted to reflect 200% attainment as of the year ended december 31, 2016. the vesting condition for psus based on baxter stock performance relative to the company's peer group is fair valued using a monte carlo model. a monte carlo model uses stock price volatility and other variables to estimate the probability of satisfying the market conditions and the resulting fair value of the award. refer to note 12 in item 8 for additional information.
certain regulatory matters in january 2014, the company received a warning letter from fda primarily directed to quality systems for the company's round lake, illinois, facility, particularly in that facility's capacity as a specification developer for certain of the company's medical devices. this warning letter was lifted in february 2017.
the company received a warning letter in december 2013 that included observations related to the company's ambulatory infuser business in irvine, california, which previously had been subject to agency action.
in june 2013, the company received a warning letter from fda regarding operations and processes at its north cove, north carolina and jayuya, puerto rico facilities and in november 2015 attended a regulatory meeting with fda concerning the jayuya facility. the warning letter addresses observations related to current good manufacturing practice (cgmp) violations at the two facilities.
in june 2010, the company received a warning letter from fda in connection with an inspection of its mcgaw park, illinois facility, which previously supported the renal franchise. the company's round lake facility now provides the related capacity for the renal franchise. the warning letter pertains to the processes by which the company analyzes and addresses product complaints through corrective and preventative action, and reports relevant information to fda. this warning letter was lifted in february 2017.
on october 9, 2014, the company had a regulatory meeting with fda to discuss the warning letters described above. at the meeting, the company agreed to work closely with fda to provide regular updates on its progress to meet all requirements and resolve all matters identified in the warning letters described above.
refer to item 1a of this annual report on form 10-k for additional discussion of regulatory matters and how they may impact the company.
forward-looking information this annual report includes forward-looking statements. use of the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "seeks," "intends," "evaluates," "pursues," "anticipates," "continues," "designs," "impacts," "affects," "forecasts," "target," "outlook," "initiative," "objective," "designed," "priorities," "goal," or the negative of those words or other similar expressions is intended to identify forward-looking statements that represent our current judgment about possible future events. these forward-looking statements may include statements with respect to accounting estimates
37
and assumptions, litigation-related matters including outcomes, future regulatory filings and the company's r&d pipeline, strategic objectives, credit exposure to foreign governments, potential developments with respect to credit ratings, investment of foreign earnings, estimates of liabilities including those related to uncertain tax positions, contingent payments, future pension plan contributions, costs, discount rates and rates of return, the company's exposure to financial market volatility and foreign currency and interest rate risks,  potential tax liability associated with the separation of the company's biopharmaceuticals and medical products businesses (including the 2016 disposition of the company's retained stake in baxalta), the impact of competition, future sales growth, business development activities, business optimization initiatives, cost saving initiatives, future capital and r&d expenditures, future debt issuances, manufacturing expansion, the sufficiency of the company's facilities and financial flexibility, the adequacy of credit facilities, tax provisions and reserves, the effective tax rate and all other statements that do not relate to historical facts.
these forward-looking statements are based on certain assumptions and analyses made in light of the company's experience and perception of historical trends, current conditions, and expected future developments as well as other factors that the company believes are appropriate in the circumstances. while these statements represent the company's current judgment on what the future may hold, and the company believes these judgments are reasonable, these statements are not guarantees of any events or financial results. whether actual future results and developments will conform to expectations and predictions is subject to a number of risks and uncertainties, including the following factors, many of which are beyond our control:
   failure to achieve our long-term financial improvement goals;

   demand for and market acceptance risks for and competitive pressures related to new and existing products, and the impact of those products on quality and patient safety concerns;

   product development risks, including satisfactory clinical performance, the ability to manufacture at appropriate scale, and the general unpredictability associated with the product development cycle;

   product quality or patient safety issues, leading to product recalls, withdrawals, launch delays, sanctions, seizures, litigation, or declining sales;

   future actions of fda, ema or any other regulatory body or government authority that could delay, limit or suspend product development, manufacturing or sale or result in seizures, recalls, injunctions, monetary sanctions or criminal or civil liabilities;

   failures with respect to the company's compliance programs;

   future actions of third parties, including third-party payers, as healthcare reform and other similar measures are implemented, modified or repealed in the united states and globally;

   the impact of ongoing u.s. healthcare reform and other similar actions undertaken by foreign governments with respect to pricing, reimbursement, taxation and rebate policies;

   additional legislation, regulation and other governmental pressures in the united states or globally, which may affect pricing, reimbursement, taxation and rebate policies of government agencies and private payers or other elements of the company's business;

   the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies;

   global regulatory, trade and tax policies;

   the company's ability to identify business development and growth opportunities and to successfully execute on business development strategies;

   the company's ability to finance and develop new products or enhancements, on commercially acceptable terms or at all;

   the availability and pricing of acceptable raw materials and component supply;

   inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties;

   the ability to protect or enforce the company's owned or in-licensed patent or other proprietary rights (including trademarks, copyrights, trade secrets and know-how) or patents of third parties preventing or restricting the company's manufacture, sale or use of affected products or technology;

   the impact of any future tax liability with respect to the separation and distribution, including with respect to disposition of the retained shares;

38
   any failure by baxalta or shire to satisfy its obligation under the separation agreements, including the tax matters agreement, or the letter agreement;

   the impact of global economic conditions on the company and its customers and suppliers, including foreign governments in certain countries in which the company operates;

   fluctuations in foreign exchange and interest rates;

   any changes in law concerning the taxation of income, including income earned outside the united states, which may be a part of comprehensive tax reform;

   actions by tax authorities in connection with ongoing tax audits;

   breaches or failures of the company's information technology systems;

   loss of key employees or inability to identify and recruit new employees;

   the outcome of pending or future litigation;

   the adequacy of the company's cash flows from operations to meet its ongoing cash obligations and fund its investment program; and

   other factors identified elsewhere in this annual report on form 10-k including those factors described in item 1a and other filings with the securities and exchange commission, all of which are available on the company's website.

actual results may differ materially from those projected in the forward-looking statements. the company does not undertake to update its forward-looking statements.
